Development of lymphangioleiomyomatosis in a female patient with Sjö gren's disease: a review of literature and a case report
https://doi.org/10.14412/1996-7012-2019-2-119-123
Abstract
Cystic and bullous lung transformation occurs in diseases of various origins: neoplastic, genetically determined, rheumatic, lymphoproliferative, and infectious diseases. The paper presents a review of the literature and a clinical case of a young female patient with a long history of Sjögren's disease. Fifteen years after the onset of the disease, the patient developed cystic and bullous lung transformation and renal angiomyolipoma, which are regarded as a manifestation of probable lymphangioleiomyomatosis.
About the Authors
Yu. I. Khvan
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
S. G. Palshina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
V. I. Vasiliev
MEDSI Clinic
Russian Federation
3A, Gruzinskiy pereulok, Moscow 123056
Russian Federation
3A, Gruzinskiy pereulok, Moscow 123056
References
1. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: Glossary of Terms for Thoracic Imaging. Radiology. 2008 Mar; 246(3):697-722. doi: 10.1148/radiol.2462070712. Epub 2008 Jan 14.
2. Gupta N, Vassallo R, WikenheiserBrokamp KA, McCormack FX. Diffuse Cystic Lung Disease Part I. Am J Respir Crit Care Med. 2015 Jun 15;191(12):1354-66. doi: 10.1164/rccm.201411-2094CI.
3. Gupta N, Vassallo R, WikenheiserBrokamp KA, McCormack FX. Diffuse Cystic Lung Disease Part II. Am J Respir Crit Care Med. 2015 Jul 1;192(1):17-29. doi: 10.1164/rccm.201411-2096CI.
4. Ferreira Francisco FA, Soares Souza A Jr, Zanetti G, Marchiori E. Multiple cystic lung disease. Eur Respir Rev. 2015 Dec;24(138): 552-64. doi: 10.1183/16000617.0046-2015.
5. Johnson SR, Taveira-DaSilva AM, Moss J. Lymphangioleiomyomatosis. Clin Chest Med. 2016 Sep;37(3):389-403. doi: 10.1016/j.ccm.2016.04.002.
6. Henske EP, McCormack FX. Lymphangioleiomyomatosis — a wolf in sheep’s clothing. J Clin Invest. 2012 Nov; 122(11):3807-16. doi: 10.1172/JCI58709. Epub 2012 Nov 1.
7. Johnson SR1, Cordier JF, Lazor R, et al; Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010 Jan;35(1): 14-26. doi: 10.1183/09031936.00076209.
8. Svobodina ON. Clinical and radiological diagnosis of lung lesions in Sjö gren’s disease. Diss. cand. med. sci. 1991.
9. Futami S, Arai T, Hirose M, et al. Comorbid connective tissue diseases and autoantibodies in lymphangioleiomyomatosis: a retrospective cohort study. Orphanet J Rare Dis. 2018 Oct 20;13(1):182. doi: 10.1186/s13023-018-0933-0.
10. Watanabe M, Naniwa T, Nara M, et al. Pulmonary Manifestations in Sjö gren’s Syndrome: Correlation Analysis Between Chest Computed Tomographic Findings and Clinical Subsets with Poor Prognosis in 80 Patients. J Rheumatol. 2010 Feb;37(2): 365-73. doi: 10.3899/jrheum.090507. Epub 2009 Dec 15.
11. Lohrmann C, Uhl M, Warnatz K, et al. High-resolution CT imaging of the lung for patients with primary Sjö gren’s syndrome. Eur J Radiol. 2004 Nov;52(2):137-43. doi:10.1016/j.ejrad.2004.01.006.
12. Honda O, Johkoh T, Ichikado K, et al. Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT. AJR Am J Roentgenol. 1999 Jul;173(1):71-4. doi: 10.2214/ajr.173.1.10397102.
13. Vasil'ev VI. Sjö gren’s syndrome. In: Nasonov EL, Nasonova VA, editors. Revmatologiya: natsional'noe rukovodstvo [Rheumatology: national guidelines]. Moscow: GEOTAR-Media; 2008. P. 495..
14. Desche P, Couderc LJ, Epardeau B. Sjö gren's syndrome and pulmonary lymphangiomyomatosis. Chest. 1988 Oct; 94(4):898.
15. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjö gren’s syndrome: a data-driven, expert consensus approach in the Sjö gren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87.
16. Shiboski CH, Shiboski SC, Seror R, et al; International Sjö gren’s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjö gren’s syndrome. Ann Rheum Dis. 2017 Jan;76(1):9-16. doi: 10.1136/annrheumdis-2016-210571. Epub 2016 Oct 26.
17. Seyama K, Kumasaka T, Souma S, et al. Vascular Endothelial Growth Factor-D Is Increased in Serum of Patients with Lymphangioleiomyomatosis. Lymphat Res Biol. 2006;4(3):143-52. doi:10.1089/lrb.2006.4.143.
18. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010 Sep;138(3):674-81. doi: 10.1378/chest.10-0573. Epub 2010 Apr 9.
19. Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med. 2013 Feb;107(2):263-8. doi: 10.1016/j.rmed.2012.10.006. Epub 2012 Nov 3.
Review
For citations:
Khvan YI, Palshina SG, Vasiliev VI. Development of lymphangioleiomyomatosis in a female patient with Sjö gren's disease: a review of literature and a case report. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(2):119-123. (In Russ.) https://doi.org/10.14412/1996-7012-2019-2-119-123
Views:
982
Email this article 